Discover the latest insights on geographic atrophy, its causes, symptoms, and innovative treatment options to manage this eye condition effectively.
Videos
Discover the latest insights on geographic atrophy, its causes, symptoms, and innovative treatment options to manage this eye condition effectively.
Explore the complexities of managing geographic atrophy in AMD patients, including treatment decisions and the importance of ongoing monitoring.
Explore the complexities of treating geographic atrophy in elderly patients, focusing on individualized care and decision-making strategies.
Explore the latest advancements in geographic atrophy management, focusing on early detection, imaging tools, and evolving treatment strategies.
Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic impact.
Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.
Dr. Sharon Fekrat presented a retrospective analysis assessing how antiplatelet and anticoagulant therapy relates to hemorrhage characteristics and outcomes.
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME.
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.
A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2.
A panelist discusses how successful NT-501 integration in MacTel care requires both strategic eye selection and overcoming financial and institutional barriers.
A panelist discusses how individualized imaging-based decisions guide when to initiate NT-501 therapy in both early and advanced stages of MacTel type 2.
A panelist discusses how strategic eye selection and proactive patient counseling optimize success and satisfaction with NT-501 implantation for bilateral MacTel type 2.
A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition.
An expert summarizes real-world GA management lessons, highlighting personalized imaging-guided care and patient-centered strategies to maintain vision stability.
An expert demonstrates how to safely co-manage AMD and GA using staggered dual-pathway treatment to maintain stability and patient confidence.
An expert outlines vision-preserving strategies for monocular high-risk GA, emphasizing early intervention and tailored therapy for safety and stability.
An expert details practical imaging and counseling strategies for slowing vision loss in geographic atrophy through case-based management and patient engagement.
A panelist discusses how integrating clinical trial data with real-world experience, patient-centered care, and shared decision-making enables retina specialists to individualize treatment plans, optimize adherence, and preserve vision in patients with geographic atrophy and neovascular AMD.
Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD
A panelist discusses how interpreting clinical trial data, monitoring disease progression, and maintaining transparent communication help retina specialists make informed decisions about when and how to treat geographic atrophy with emerging therapies.
Dr. Singh reported that when technicians understand why they are performing a diagnostic test, they perform better and think critically in patient care situations.
Data suggests the candidate can reduce the number of injections and treatment burden for patients
In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.
The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.
A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient communication to build confidence and personalize treatment in evolving clinical settings.
Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
